Literature DB >> 12089359

The mRNA structure has potent regulatory effects on type 2 iodothyronine deiodinase expression.

Balázs Gereben1, Anna Kollár, John W Harney, P Reed Larsen.   

Abstract

Type 2 deiodinase (D2) is a selenoenzyme catalyzing the activation of T(4) to T(3). D2 activity/mRNA ratios are often low, suggesting that there is significant posttranscriptional regulation. The D2 mRNA in higher vertebrates is more than 6 kb, containing long 5' and 3' untranslated regions (UTRs). The D2 5'UTRs are greater than 600 nucleotides and contain 3-5 short open reading frames. These full-length 5'UTRs reduce the D2 translation efficiency approximately 5-fold. The inhibition by human D2 5'UTR is localized to a region containing the first short open reading frame encoding a tripeptide-MKG. This inhibition was abolished by mutating the AUG start codon and weakened by modification of the essential purine of the Kozak consensus. Deletion of the 3.7-kb 3'UTR of the chicken D2 mRNA increased D2 activity approximately 3.8-fold due to an increase in D2 mRNA half-life. In addition, alternatively spliced D2 mRNA transcripts similar in size to the major 6- to 7-kb D2 mRNAs but not encoding an active enzyme are present in both human and chicken tissues. Our results indicate that a number of factors reduce the D2 protein levels. These mechanisms, together with the short half-life of the protein, ensure limited expression of this key regulator of T(4) activation.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12089359     DOI: 10.1210/mend.16.7.0879

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  13 in total

1.  Endoplasmic reticulum stress decreases intracellular thyroid hormone activation via an eIF2a-mediated decrease in type 2 deiodinase synthesis.

Authors:  Rafael Arrojo E Drigo; Tatiana L Fonseca; Melany Castillo; Matthias Salathe; Gordana Simovic; Petra Mohácsik; Balazs Gereben; Antonio C Bianco
Journal:  Mol Endocrinol       Date:  2011-11-03

Review 2.  Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling.

Authors:  Balázs Gereben; Ann Marie Zavacki; Scott Ribich; Brian W Kim; Stephen A Huang; Warner S Simonides; Anikó Zeöld; Antonio C Bianco
Journal:  Endocr Rev       Date:  2008-09-24       Impact factor: 19.871

Review 3.  Paradigms of Dynamic Control of Thyroid Hormone Signaling.

Authors:  Antonio C Bianco; Alexandra Dumitrescu; Balázs Gereben; Miriam O Ribeiro; Tatiana L Fonseca; Gustavo W Fernandes; Barbara M L C Bocco
Journal:  Endocr Rev       Date:  2019-08-01       Impact factor: 19.871

4.  Thyroid hormone deiodinases D1, D2, and D3 are expressed in human endothelial dermal microvascular line: effects of thyroid hormones.

Authors:  Laura Sabatino; Valter Lubrano; Silvana Balzan; Claudia Kusmic; Serena Del Turco; Giorgio Iervasi
Journal:  Mol Cell Biochem       Date:  2014-10-11       Impact factor: 3.396

Review 5.  Iodothyronine deiodinases and cancer.

Authors:  A Piekiełko-Witkowska; A Nauman
Journal:  J Endocrinol Invest       Date:  2011-05-27       Impact factor: 4.256

6.  Type 2 deiodinase and host responses of sepsis and acute lung injury.

Authors:  Shwu-Fan Ma; Lishi Xie; Maria Pino-Yanes; Saad Sammani; Michael S Wade; Eleftheria Letsiou; Jessica Siegler; Ting Wang; Giovanni Infusino; Rick A Kittles; Carlos Flores; Tong Zhou; Bellur S Prabhakar; Liliana Moreno-Vinasco; Jesus Villar; Jeffrey R Jacobson; Steven M Dudek; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2011-06-17       Impact factor: 6.914

7.  Contributions of HIV infection in the hypothalamus and substance abuse/use to HPT dysregulation.

Authors:  Dianne Langford; David Baron; Javed Joy; Luis Del Valle; Jonathon Shack
Journal:  Psychoneuroendocrinology       Date:  2010-11-05       Impact factor: 4.905

8.  Activation of thyroid hormone is transcriptionally regulated by epidermal growth factor in human placenta-derived JEG3 cells.

Authors:  Gianluca Canettieri; Antonella Franchi; Michele Della Guardia; Ianessa Morantte; Maria Giulia Santaguida; John W Harney; P Reed Larsen; Marco Centanni
Journal:  Endocrinology       Date:  2007-11-08       Impact factor: 4.736

9.  Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.

Authors:  Ana B Santoro; Daniela D Vargens; Mateus de Camargo Barros Filho; Daniel A Bulzico; Luiz Paulo Kowalski; Ricardo M R Meirelles; Daniela P Paula; Ronaldo R S Neves; Cencita N Pessoa; Claudio J Struchine; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

10.  Quantitative trait loci associated with elevated thyroid-stimulating hormone in the Wistar-Kyoto rat.

Authors:  Amber E Baum; Leah C Solberg; Peter Kopp; Nasim Ahmadiyeh; Gary Churchill; Joseph S Takahashi; J Larry Jameson; Eva E Redei
Journal:  Endocrinology       Date:  2004-10-28       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.